Oragenics Stock Price, News & Analysis (NYSEAMERICAN:OGEN) $3.46 -0.12 (-3.35%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$3.46▼$3.8050-Day Range$2.94▼$4.1852-Week Range$2.60▼$12.33Volume7,923 shsAverage Volume3,952 shsMarket Capitalization$8.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Oragenics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingSelling Shares$12,495 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.44 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Oragenics. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.11% of the float of Oragenics has been sold short.Short Interest Ratio / Days to CoverOragenics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oragenics has recently decreased by 12.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOragenics does not currently pay a dividend.Dividend GrowthOragenics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OGEN. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Oragenics this week, compared to 0 articles on an average week.Search Interest2 people have searched for OGEN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Oragenics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oragenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,495.00 in company stock.Percentage Held by Insiders24.60% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.07% of the stock of Oragenics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOragenics has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oragenics Stock (NYSEAMERICAN:OGEN)Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Read More OGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OGEN Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Oragenics (NYSEAMERICAN:OGEN)November 26, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Oragenics (NYSEAMERICAN:OGEN)December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 6, 2023 | finance.yahoo.comOragenics, Inc. (UAV.F)November 2, 2023 | finance.yahoo.comOragenics Issues Update to ShareholdersOctober 5, 2023 | marketwatch.comOragenics Shares Rise 15% After Deal to Buy Some Odyssey Health AssetsOctober 5, 2023 | finance.yahoo.comOragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug CandidateOctober 2, 2023 | msn.comOragenics, AVITA Medical among healthcare moversDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.September 29, 2023 | marketwatch.comStocks to Watch: Oragenics, Natuzzi, Syndax PharmaceuticalsSeptember 29, 2023 | finance.yahoo.comOragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy AssetsAugust 7, 2023 | finance.yahoo.comOragenics, Inc. Announces Private PlacementJune 5, 2023 | finance.yahoo.comOragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDMMarch 29, 2023 | finance.yahoo.comOragenics to Participate in the World Vaccine Congress WashingtonMarch 14, 2023 | finance.yahoo.comOragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VREMarch 8, 2023 | finance.yahoo.comOragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership TeamMarch 1, 2023 | finance.yahoo.comOragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing PactMarch 1, 2023 | finance.yahoo.comOragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine CandidateFebruary 3, 2023 | financialpost.comOragenics, Inc. Regains Compliance with NYSE AmericanDecember 23, 2022 | finance.yahoo.comOragenics, Inc. Discloses One-for-Sixty Reverse Stock SplitDecember 22, 2022 | finance.yahoo.comOragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine CandidateDecember 20, 2022 | finance.yahoo.comOragenics, Inc. Receives NYSE American NoticeDecember 19, 2022 | financialpost.comOragenics, Inc. Announces New ChairOctober 24, 2022 | finance.yahoo.comOragenics to Participate in the 2022 BioFlorida Annual ConferenceSeptember 30, 2022 | benzinga.comOral & Dental Probiotics Market Size & Shares by 2027 | Revenue, Cost Analysis, Gross Margins, Future Inv - BenzingaSeptember 9, 2022 | morningstar.comOragenics Inc OGEN Stock QuoteSeptember 7, 2022 | reuters.comOGEN.P - Oragenics Inc | Stock Price & Latest News | ReutersSee More Headlines Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:OGEN CUSIPN/A CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,290,000.00 Net MarginsN/A Pretax Margin-26,700.00% Return on Equity-132.48% Return on Assets-93.84% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$130,000.00 Price / Sales68.40 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book1.81Miscellaneous Outstanding Shares2,570,000Free Float1,937,000Market Cap$8.89 million OptionableNot Optionable Beta0.53 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Kimberly M. Murphy (Age 60)President, CEO & Director Comp: $497.03kMs. Janet Huffman (Age 51)CFO, Secretary & Treasurer Key CompetitorsTenax TherapeuticsNASDAQ:TENXEdesa BiotechNASDAQ:EDSANightHawk BiosciencesNYSE:NHWKGT BiopharmaNASDAQ:GTBPImunonNASDAQ:IMNNView All CompetitorsInsidersFred TellingSold 3,500 sharesTotal: $12,495.00 ($3.57/share)Robert C KoskiSold 813 sharesTotal: $9,756.00 ($12.00/share)View All Insider Transactions OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed in 2023? Oragenics' stock was trading at $0.1051 at the beginning of 2023. Since then, OGEN stock has increased by 3,192.1% and is now trading at $3.46. View the best growth stocks for 2023 here. Are investors shorting Oragenics? Oragenics saw a decrease in short interest in October. As of October 31st, there was short interest totaling 52,400 shares, a decrease of 25.9% from the October 15th total of 70,700 shares. Based on an average trading volume of 17,400 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.5% of the shares of the company are short sold. View Oragenics' Short Interest. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.85) EPS for the quarter. The biotechnology company earned $0.01 million during the quarter. When did Oragenics' stock split? Oragenics shares reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Imunon (CLSN), Jaguar Health (JAGX), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV). How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:OGEN) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.